Published in Proc Natl Acad Sci U S A on January 05, 1999
The COX-2 Gene and the Immune System | NCT01678222
BONSAI: Biomarkers of Nonsteroidal Anti-Inflammatories | NCT00239746
Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol (2011) 4.67
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest (2006) 4.50
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation (2008) 3.63
Prostaglandins and cancer. Gut (2005) 3.44
The double-edged sword of COX-2 selective NSAIDs. CMAJ (2002) 2.57
Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci U S A (2000) 2.28
Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest (2001) 2.19
Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest (2004) 2.12
Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res (Phila) (2009) 2.06
Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest (2006) 2.03
Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol (1999) 2.00
Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res (2002) 1.90
Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest (2002) 1.86
Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest (2000) 1.78
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med (2006) 1.71
Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med (2012) 1.71
Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol (1999) 1.65
Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol (2011) 1.51
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest (2001) 1.45
Adiponectin promotes revascularization of ischemic muscle through a cyclooxygenase 2-dependent mechanism. Mol Cell Biol (2009) 1.40
Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A (2001) 1.38
Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A (2012) 1.35
Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett (2008) 1.32
Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer. J Biol Chem (2011) 1.31
Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis (2003) 1.31
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
Do nonsteroidal anti-inflammatory drugs affect bone healing? A critical analysis. ScientificWorldJournal (2012) 1.29
Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut (2001) 1.29
The endothelium and its role in regulating vascular tone. Open Cardiovasc Med J (2010) 1.21
Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut (2003) 1.20
Eicosanoid signalling pathways in the heart. Cardiovasc Res (2008) 1.19
Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res (2008) 1.17
COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. J Exp Med (2007) 1.16
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci U S A (2001) 1.13
Potential roles of microsomal prostaglandin E synthase-1 in rheumatoid arthritis. Inflamm Regen (2011) 1.11
Adventures in vascular biology: a tale of two mediators. Philos Trans R Soc Lond B Biol Sci (2006) 1.10
Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol (2000) 1.09
Vasoconstrictor prostanoids. Pflugers Arch (2010) 1.09
Ischemic preconditioning via epsilon protein kinase C activation requires cyclooxygenase-2 activation in vitro. Neuroscience (2007) 1.06
Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutat Res (2010) 1.06
Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse. PLoS One (2011) 1.06
Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut (2001) 1.05
NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells. Mol Cancer Ther (2009) 1.05
Pathway-oriented profiling of lipid mediators in macrophages. Biochem Biophys Res Commun (2005) 1.05
A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. Pharmacogenomics J (2008) 1.04
Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer (2006) 1.03
Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood (2006) 1.03
Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol (2001) 1.03
Identification of key residues determining species differences in inhibitor binding of microsomal prostaglandin E synthase-1. J Biol Chem (2010) 1.02
Gastrointestinal damage induced by celecoxib and rofecoxib in rats. Dig Dis Sci (2001) 1.02
Interaction between head and neck squamous cell carcinoma cells and fibroblasts in the biosynthesis of PGE2. J Lipid Res (2012) 1.01
Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. Cancer Prev Res (Phila) (2011) 1.00
Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol (2011) 0.99
Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2. J Mol Cell Cardiol (2010) 0.99
Increased superoxide and endothelial NO synthase uncoupling in blood vessels of Bmal1-knockout mice. Circ Res (2012) 0.99
Non-steroid anti-inflammatory drugs, prostaglandins, and cancer. Cell Biosci (2013) 0.99
Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. Proc Natl Acad Sci U S A (2012) 0.98
Cyclo-oxygenase-2 mediated prostaglandin release regulates blood flow in connective tissue during mechanical loading in humans. J Physiol (2003) 0.98
Fish oil: what the prescriber needs to know. Arthritis Res Ther (2006) 0.97
Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacol Rev (2012) 0.97
Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation. J Clin Invest (2004) 0.97
Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy. Mol Cancer (2009) 0.97
The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland. Br J Clin Pharmacol (2006) 0.95
Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress. Neuro Oncol (2013) 0.94
Aspirin and other anti-inflammatory drugs. Thorax (2000) 0.93
Coxibs: can this class of drugs survive? Vasc Health Risk Manag (2005) 0.93
Complicity theory: an explanation for the 'coxib problem'? J R Soc Med (2006) 0.92
Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. Br J Pharmacol (2002) 0.92
Cyclooxygenase-2-dependent prostacyclin formation and blood pressure homeostasis: targeted exchange of cyclooxygenase isoforms in mice. Circ Res (2009) 0.92
The role of inflammatory processes in Alzheimer's disease. Inflammopharmacology (2012) 0.92
Acyl chain-dependent effect of lysophosphatidylcholine on endothelial prostacyclin production. J Lipid Res (2010) 0.91
Endothelial dysfunction in mice with streptozotocin-induced type 1 diabetes is opposed by compensatory overexpression of cyclooxygenase-2 in the vasculature. Endocrinology (2008) 0.90
4 years after withdrawal of rofecoxib: where do we stand today? Rheumatol Int (2008) 0.90
Adenylyl cyclase type 6 overexpression selectively enhances beta-adrenergic and prostacyclin receptor-mediated inhibition of cardiac fibroblast function because of colocalization in lipid rafts. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.89
Cyclo-oxygenase-2 inhibition increases blood pressure in rats. Br J Pharmacol (2002) 0.89
Acyl chain-dependent effect of lysophosphatidylcholine on cyclooxygenase (COX)-2 expression in endothelial cells. Atherosclerosis (2012) 0.88
Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. Vasc Health Risk Manag (2005) 0.88
Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk. Rheumatol Int (2007) 0.87
Interaction of the human prostacyclin receptor with Rab11: characterization of a novel Rab11 binding domain within alpha-helix 8 that is regulated by palmitoylation. J Biol Chem (2010) 0.87
Prostanoids and blood pressure: which way is up? J Clin Invest (2004) 0.87
Effect of sphingosine kinase 1 inhibition on blood pressure. FASEB J (2012) 0.86
Thromboxane and the thromboxane receptor in cardiovascular disease. Clin Lipidol (2010) 0.86
Role of cyclooxygenase isoforms in prostacyclin biosynthesis and murine prehepatic portal hypertension. Am J Physiol Gastrointest Liver Physiol (2008) 0.86
Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro Oncol (2008) 0.86
Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. Vasc Health Risk Manag (2006) 0.86
Inducible nitric oxide synthase mediates prostaglandin h2 synthase nitration and suppresses eicosanoid production. Am J Pathol (2006) 0.86
Agonist-dependent internalization and trafficking of the human prostacyclin receptor: a direct role for Rab5a GTPase. Biochim Biophys Acta (2008) 0.86
Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium. J Thorac Cardiovasc Surg (2010) 0.85
Hypoxia upregulates PGI-synthase and increases PGI₂ release in human vascular cells exposed to inflammatory stimuli. J Lipid Res (2011) 0.85
Cyclooxygenase expression and platelet function in healthy dogs receiving low-dose aspirin. J Vet Intern Med (2012) 0.85
Prostaglandins and rheumatoid arthritis. Arthritis (2012) 0.85
The choreography of cyclooxygenases in the kidney. J Clin Invest (2002) 0.85
Microsomal prostaglandin E synthase-1 and cyclooxygenase-2 are both required for ischaemic excitotoxicity. Br J Pharmacol (2010) 0.84
Effects of nitric oxide synthase inhibition with or without cyclooxygenase-2 inhibition on resting haemodynamics and responses to exendin-4. Br J Pharmacol (2006) 0.84
Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on myocardial function and perfusion. J Cardiovasc Pharmacol (2011) 0.84
Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-I(Milano). J Cell Mol Med (2008) 0.84
Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics (2012) 0.84
Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo. Prostate (2010) 0.84
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol (1971) 37.53
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell (1995) 6.69
Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A (1992) 5.21
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (1997) 5.11
Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A (1991) 5.07
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A (1993) 4.82
Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell (1995) 4.47
Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A (1994) 4.21
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A (1994) 4.15
Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A (1996) 3.93
cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci U S A (1992) 3.65
Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature (1997) 3.07
Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells. J Biol Chem (1990) 3.02
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest (1997) 2.99
Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res (1980) 2.68
Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest (1990) 2.66
Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem (1993) 2.61
Platelet activation in unstable coronary disease. N Engl J Med (1986) 2.60
Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol (1996) 2.52
Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett (1993) 2.41
The eicosanoids and their biochemical mechanisms of action. Biochem J (1989) 2.35
Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest (1994) 2.29
Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest (1982) 2.23
Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest (1983) 2.13
Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J (1987) 2.11
Prostanoid biosynthesis and mechanisms of action. Am J Physiol (1992) 2.05
Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science (1998) 2.03
Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med (1984) 2.00
Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood (1987) 1.96
Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem (1995) 1.82
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum (1998) 1.79
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther (1994) 1.79
Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther (1994) 1.75
Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J Clin Invest (1994) 1.74
Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation (1983) 1.73
Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2. J Biol Chem (1993) 1.65
A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem (1996) 1.61
Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med (1991) 1.58
Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J (1991) 1.54
Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol (1997) 1.44
Expression of the protein product of the prostaglandin synthase-2/TIS10 gene in mitogen-stimulated Swiss 3T3 cells. J Biol Chem (1993) 1.41
11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci U S A (1986) 1.35
Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol (1995) 1.27
Lipopolysaccharide induces prostaglandin H synthase-2 in alveolar macrophages. Biochem Biophys Res Commun (1992) 1.25
Interleukin 10 suppression of monocyte prostaglandin H synthase-2. Mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production. J Biol Chem (1994) 1.19
Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res (1987) 1.15
Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am (1996) 1.08
The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation (1985) 1.05
A better understanding of anti-inflammatory drugs based on isoforms of cyclooxygenase (COX-1 and COX-2). Adv Prostaglandin Thromboxane Leukot Res (1995) 1.02
Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler Thromb (1994) 1.02
Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils. Blood (1997) 1.01
Prostaglandin G/H synthase isoenzyme 2 expression in fibroblasts: regulation by dexamethasone, mitogens, and oncogenes. Arch Biochem Biophys (1993) 1.01
Presystemic acetylation of platelets by aspirin: reduction in rate of drug delivery to improve biochemical selectivity for thromboxane A2. J Pharmacol Exp Ther (1991) 0.98
Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin. Circulation (1991) 0.97
Metabolic disposition of prostacyclin in humans. J Pharmacol Exp Ther (1983) 0.97
Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci (1994) 0.94
1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2. J Med Chem (1997) 0.93
Differential sensitivities of human blood monocytes and alveolar macrophages to the inhibition of prostaglandin endoperoxide synthase-2 by interleukin-4. Prostaglandins (1997) 0.87
1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents. J Med Chem (1997) 0.86
Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men. Thromb Res (1988) 0.86
Mechanisms of NSAID-induced gastroenteropathy. Drugs (1990) 0.84
Measurement of thromboxane metabolites by gas chromatography-mass spectrometry. Methods Enzymol (1990) 0.82
Simultaneous mass spectrometric measurement of prostaglandins E1 (PGE1) and PGE2 with a deuterated internal standard. Lipids (1979) 0.81
Changes in peripheral hemodynamics and vasodilating prostaglandins after high-dose short-term ibuprofen in chronically treated hypertensive patients. Prostaglandins Leukot Essent Fatty Acids (1996) 0.79
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med (2001) 5.96
Acute admissions to medical beds. J R Coll Gen Pract (1972) 3.80
Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med (2005) 3.13
Platelet activation in unstable coronary disease. N Engl J Med (1986) 2.60
Regulation of CLOCK and MOP4 by nuclear hormone receptors in the vasculature: a humoral mechanism to reset a peripheral clock. Cell (2001) 2.59
Effects of vitamin E on lipid peroxidation in healthy persons. JAMA (2001) 2.58
The antihypertensive effects of fish oil. A controlled study of polyunsaturated fatty acid supplements in essential hypertension. N Engl J Med (1989) 2.36
No evidence for lipid peroxidation in severe preeclampsia. Am J Obstet Gynecol (2001) 2.28
Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. Arthritis Rheum (2000) 2.26
Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest (2001) 2.25
Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest (2001) 2.19
Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest (1981) 2.18
Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest (1983) 2.13
Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther (1999) 2.10
Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med (1984) 2.00
Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med (1998) 1.98
Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood (1987) 1.96
Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest (1997) 1.90
The intubating laryngeal mask airway after induction of general anesthesia versus awake fiberoptic intubation in patients with difficult airways. Anesth Analg (2001) 1.85
Activation of caspase 3 (CPP32)-like proteases is essential for TNF-alpha-induced hepatic parenchymal cell apoptosis and neutrophil-mediated necrosis in a murine endotoxin shock model. J Immunol (1998) 1.82
Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation (1999) 1.79
Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol (2000) 1.79
Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest (2000) 1.78
Radiofrequency sacroiliac joint denervation for sacroiliac syndrome. Reg Anesth Pain Med (2001) 1.77
Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation (1991) 1.74
Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation (1996) 1.74
Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation (1983) 1.73
Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med (1984) 1.73
Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest (1998) 1.73
Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J Am Coll Cardiol (2001) 1.71
Increased blood pressure during potassium depletion in normotensive men. N Engl J Med (1989) 1.69
A double blind placebo controlled crossover study of prostacyclin in man. Life Sci (1979) 1.67
Occupational asthma in newly employed workers in intensive swine confinement facilities. Eur Respir J (2004) 1.63
Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J Biol Chem (1993) 1.59
Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes (1997) 1.59
Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med (1991) 1.58
Thromboxane A2 synthesis in pregnancy-induced hypertension. Lancet (1990) 1.56
A new Vibrio fischeri lux gene precedes a bidirectional termination site for the lux operon. J Bacteriol (1990) 1.55
Alcohol-induced generation of lipid peroxidation products in humans. J Clin Invest (1999) 1.55
Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets that had undergone anoxia and then reoxygenated. Circulation (1997) 1.54
Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol (1997) 1.53
Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem (1999) 1.53
Two polymorphisms in the human lipoprotein lipase (LPL) gene. Nucleic Acids Res (1987) 1.51
Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation (1988) 1.49
Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. J Vasc Surg (1999) 1.49
Elevated levels of IL-8 in dengue hemorrhagic fever. J Med Virol (1998) 1.49
Indices of lipid peroxidation in vivo: strengths and limitations. Free Radic Biol Med (2000) 1.48
Dipyridamole. N Engl J Med (1987) 1.48
Follicular phase hormone levels and menstrual bleeding status in the approach to menopause. Fertil Steril (2005) 1.47
Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation (2001) 1.46
Effects of celecoxib on major prostaglandins in asthma. Clin Exp Allergy (2010) 1.45
Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F(2)-isoprostanes in human urine. Proc Natl Acad Sci U S A (1999) 1.45
Clinical implications of prostaglandin and thromboxane A2 formation (1). N Engl J Med (1988) 1.45
The Ilizarov method in infected nonunion of fractures. Injury (2000) 1.44
IPF2alpha-I: an index of lipid peroxidation in humans. Proc Natl Acad Sci U S A (1998) 1.43
Biomarkers of oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. Free Radic Biol Med (2005) 1.42
8-epi PGF2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. Circulation (1997) 1.41
A new strategy of drug treatment in NSAID-unresponsive ankylosing spondylitis: combination of pamidronate and methylprednisolone monthly intravenous infusions on the background of a combination of disease modifying drugs sulfasalazine and methotrexate. J Assoc Physicians India (2007) 1.39
HIV infection in the blood donors of Delhi, India: 1 1/2 years' experience. J Acquir Immune Defic Syndr (1991) 1.39
Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A (2001) 1.38
Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci U S A (1990) 1.38
Confusion in reperfusion. Problems in the clinical development of antithrombotic drugs. Circulation (1997) 1.38
Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest (1997) 1.38
Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus. J Neurosci (2011) 1.37
In vivo indexes of platelet and vascular function during fish-oil administration in patients with atherosclerosis. N Engl J Med (1986) 1.36
Rac1 is crucial for Ras-dependent skin tumor formation by controlling Pak1-Mek-Erk hyperactivation and hyperproliferation in vivo. Oncogene (2010) 1.35
A clinical study of the patients with dengue hemorrhagic fever during the epidemic of 1996 at Lucknow, India. Southeast Asian J Trop Med Public Health (1999) 1.35
11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci U S A (1986) 1.35
Protection against Fas receptor-mediated apoptosis in hepatocytes and nonparenchymal cells by a caspase-8 inhibitor in vivo: evidence for a postmitochondrial processing of caspase-8. Toxicol Sci (2000) 1.30
Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest (2001) 1.29
The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. J Biol Chem (1990) 1.29
The isoprostanes in biology and medicine. Trends Endocrinol Metab (2001) 1.29
Cyclooxygenase-dependent formation of the isoprostane, 8-epi prostaglandin F2 alpha. J Biol Chem (1995) 1.28
Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation (1987) 1.27
Validation of a new quality of life measure for children with epilepsy. Epilepsia (2000) 1.25
Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest (1999) 1.25
Increased formation of the isoprostanes IPF2alpha-I and 8-epi-prostaglandin F2alpha in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation (1997) 1.23
Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem (2001) 1.23
Glutathione peroxidase-deficient mice are more susceptible to neutrophil-mediated hepatic parenchymal cell injury during endotoxemia: importance of an intracellular oxidant stress. Hepatology (1999) 1.23